We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam (ALNY) to Continue Phase III Study on Patisiran
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that the Data Monitoring Committee (DMC) has recommended the continuation of the phase III APOLLO study on patisiran without any modification. However, the committee also stated that it will periodically meet to monitor the overall safety of the candidate through the course of the study.
Note that patisiran, an experimental RNAi therapeutics targeting transthyretin (TTR), is being evaluated for the treatment of hereditary TTR-mediated amyloidosis (hATTR) with polyneuropathy (hATTR-PN), also known as familial amyloidotic polyneuropathy (FAP).
Top-line data from the study are expected in mid 2017.
The committee met at Alnylam’s request following its decision to discontinue the development of revusiran in the phase III ENDEAVOUR study due to an imbalance in mortality in patients dosed with the candidate, compared to placebo. Revusiran was being evaluated for the treatment of patients with hATTR with cardiomyopathy (hATTR-CM), also known as familial amyloidotic cardiomyopathy (FAC).
We remind investors that Alnylam has a worldwide collaboration agreement with Sanofi (SNY - Free Report) for the development and commercialization of RNAi therapeutics - patisiran and revusiran.
Investors should note that hATTR represents high unmet need due to the lack of treatment options, with approximately 10,000 people affected with FAP and at least 40,000 people suffering from FAC in the world.
Meanwhile, given that Alnylam has no approved product in its portfolio, successful development of patisiran would allow the company to launch its first product.
The company currently carries a Zacks Rank #3 (Hold).
Incyte’s earnings estimates for 2016 and 2017 were up a respective 29.5% and 11.5% over the last 60 days. The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335.16%.
Geron has delivered a positive earnings surprise in each of four trailing quarters, bringing the average beat to 20.78%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Alnylam (ALNY) to Continue Phase III Study on Patisiran
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that the Data Monitoring Committee (DMC) has recommended the continuation of the phase III APOLLO study on patisiran without any modification. However, the committee also stated that it will periodically meet to monitor the overall safety of the candidate through the course of the study.
Note that patisiran, an experimental RNAi therapeutics targeting transthyretin (TTR), is being evaluated for the treatment of hereditary TTR-mediated amyloidosis (hATTR) with polyneuropathy (hATTR-PN), also known as familial amyloidotic polyneuropathy (FAP).
Top-line data from the study are expected in mid 2017.
ALNYLAM PHARMA Price
ALNYLAM PHARMA Price | ALNYLAM PHARMA Quote
The committee met at Alnylam’s request following its decision to discontinue the development of revusiran in the phase III ENDEAVOUR study due to an imbalance in mortality in patients dosed with the candidate, compared to placebo. Revusiran was being evaluated for the treatment of patients with hATTR with cardiomyopathy (hATTR-CM), also known as familial amyloidotic cardiomyopathy (FAC).
We remind investors that Alnylam has a worldwide collaboration agreement with Sanofi (SNY - Free Report) for the development and commercialization of RNAi therapeutics - patisiran and revusiran.
Investors should note that hATTR represents high unmet need due to the lack of treatment options, with approximately 10,000 people affected with FAP and at least 40,000 people suffering from FAC in the world.
Meanwhile, given that Alnylam has no approved product in its portfolio, successful development of patisiran would allow the company to launch its first product.
The company currently carries a Zacks Rank #3 (Hold).
Stocks to Consider
A couple of better-ranked stocks in the health care sector are Incyte Corporation (INCY - Free Report) and Geron Corporation (GERN - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Incyte’s earnings estimates for 2016 and 2017 were up a respective 29.5% and 11.5% over the last 60 days. The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335.16%.
Geron has delivered a positive earnings surprise in each of four trailing quarters, bringing the average beat to 20.78%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>